<DOC>
	<DOCNO>NCT00612014</DOCNO>
	<brief_summary>The purpose study determine whether TZP-101 effective treatment symptomatic gastroparesis due diabetes .</brief_summary>
	<brief_title>Safety Efficacy IV Infusion Investigational Agent ( TZP-101 ) Patients With Severe Diabetic Gastroparesis</brief_title>
	<detailed_description>Subjects randomize accord adaptive randomization procedure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>Subject type 1 type 2 diabetes mellitus Subject document diagnosis gastroparesis ( follow apply ) : Confirmed delayed gastric emptying ( see Appendix IV ; properly conduct gastric empty assessment within last 6 month acceptable ) AND minimum 3 month history relevant symptom gastroparesis ( chronic postprandial fullness , bloating , epigastric discomfort , early satiety , belch meal , postprandial nausea , vomit ) . AND mean Gastroparesis Cardinal Symptom Index ( GCSI ) Score ( 2 week recall version ) ≥ 2.66 AND confirm endoscope obstructive lesion esophagus stomach ( endoscopy within prior 3 month acceptable ) Subject never gastrectomy , major abdominal surgery evidence bowel obstruction within previous 12 month Dosage concomitant medication stable least 3 week HbA1c level ≤ 10.0 % Subject BMI &lt; 30 Subject body weight ≤ 100 kg If female , postmenopausal past 12 month , surgically sterile ( i.e . tubal ligation , hysterectomy ) , use adequate method birth control ( i.e. , oral contraceptive , double barrier method , IUD cover ) sterilize partner Subject acute severe gastroenteritis Subject gastric pacemaker Subject chronic parenteral feed Subject daily persistent severe vomit Subject pronounced dehydration Subject diabetic ketoacidosis last 4 week Subject history eat disorder ( anorexia nervosa , binge eating , bulimia ) Subject mark baseline prolongation QT/QTc interval ( repeat demonstration QTc interval &gt; 450 m male / &gt; 470 m female ) Subject history additional risk factor Torsades de Pointes ( heart failure , chronic hypokalemia , family history Long QT Syndrome ) Subject require use concomitant medication prolongs QT interval List provide clinical site Subject history cardiovascular ischemia previous 12 month acute myocardial infarction ( MI ) unstable angina Subject require use concomitant medication know interact isoenzyme CYP3A4 combination CYP3A4 inhibitor know introduce clinically significant drug interaction List provide clinical site Subject history psychiatric disorder cognitive impairment would interfere participation study Subject history alcoholism Subject take regular daily narcotic Subject know history Hep B , Hep C HIV Subject severely impair renal function ( creatinine clearance &lt; 30 mL/min ) Subject severe impairment liver function , define albumin level ≤ 2.5 gm/dL and/or prothrombin time &gt; 6 second control ( INR &gt; 2.3 ) Subject participate investigational study within 30 day prior receive TZP101 within 90 day prior study initiation Subject pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>delay gastric empty</keyword>
	<keyword>symptomatic gastroparesis</keyword>
	<keyword>diabetes mellitus</keyword>
</DOC>